Custodis Florian, Eberl Marcel, Kilter Heiko, Böhm Michael, Laufs Ulrich
Klinik und Poliklinik für Innere Medizin III, Universität des Saarlandes, Homburg/Saar, Germany.
Cardiovasc Res. 2006 Jul 15;71(2):342-51. doi: 10.1016/j.cardiores.2006.04.005. Epub 2006 Apr 19.
Reactive oxygen species (ROS) contribute to the pathogenesis of myocardial hypertrophy. NADPH oxidase is a major source of ROS production. The small GTPase Rac1 mediates the activation of NADPH oxidase; however, the mechanism of Rac1 activation is incompletely understood.
Transaortic constriction (TAC, C57/Bl6 mice, 360 microm, 21 days) increased the ratio of heart to body weight from [ per thousand] SHAM 4.16+/-0.09 to TAC 7.1+/-0.37, p<0.01. Treatment with rosuvastatin prevented pressure-induced cardiac hypertrophy (5.5+/-0.18, p<0.05). TAC induced a 4-fold up-regulation of myocardial NADPH oxidase activity as well as Rac1 activity; both effects were absent in statin-treated animals. In cultured rat cardiomyocytes, treatment with angiotensin II (AngII) increased translocation of Rac1 to cell membranes and Rac1 activity. AngII altered neither expression nor tyrosine phosphorylation of GTPase activating protein GAP-p190 and the guanine nucleotide exchange factors Vav and Tiam. Transaortic constriction as well as AngII increased the binding of Rho guanine nucleotide dissociation inhibitor (RhoGDIalpha) to Rac1. The association of RhoGDIalpha with Rac1 was mediated by phosphatidylinositol 3-kinase and depended on geranylgeranylation. Statin treatment inhibited RhoGDIalpha-Rac1 binding both in cultured cardiomyocytes and during myocardial hypertrophy in vivo. Transfection with RhoGDIalpha siRNA constructs potently reduced RhoGDIalpha protein expression, decreased AngII-induced superoxide production and lipid peroxidation, and inhibited AngII-induced leucine incorporation.
Myocardial hypertrophy is characterized by activation of Rac1 and NADPH oxidase. The association of the regulatory protein RhoGDIalpha with Rac1 represents a necessary step in the Rac1-dependent release of ROS. Rac1-RhoGDIalpha binding may represent a target for anti-hypertrophic pharmacologic interventions, potentially by statin treatment.
活性氧(ROS)参与心肌肥大的发病机制。NADPH氧化酶是ROS产生的主要来源。小GTP酶Rac1介导NADPH氧化酶的激活;然而,Rac1激活的机制尚未完全阐明。
经主动脉缩窄术(TAC,C57/Bl6小鼠,360微米,21天)使心脏与体重之比从假手术组的4.16±0.09增加到TAC组的7.1±0.37,p<0.01。瑞舒伐他汀治疗可预防压力诱导的心脏肥大(5.5±0.18,p<0.05)。TAC诱导心肌NADPH氧化酶活性以及Rac1活性上调4倍;他汀治疗的动物未出现这两种效应。在培养的大鼠心肌细胞中,用血管紧张素II(AngII)处理可增加Rac1向细胞膜的转位以及Rac1活性。AngII既未改变GTP酶激活蛋白GAP-p190以及鸟嘌呤核苷酸交换因子Vav和Tiam的表达,也未改变其酪氨酸磷酸化。经主动脉缩窄术以及AngII均增加了Rho鸟嘌呤核苷酸解离抑制剂(RhoGDIα)与Rac1的结合。RhoGDIα与Rac1的结合由磷脂酰肌醇3激酶介导,并依赖于香叶基香叶基化。他汀治疗在培养的心肌细胞以及体内心肌肥大过程中均抑制RhoGDIα-Rac1结合。用RhoGDIα siRNA构建体转染可有效降低RhoGDIα蛋白表达,减少AngII诱导的超氧化物产生和脂质过氧化,并抑制AngII诱导的亮氨酸掺入。
心肌肥大的特征是Rac1和NADPH氧化酶的激活。调节蛋白RhoGDIα与Rac1的结合是Rac1依赖性ROS释放的必要步骤。Rac1-RhoGDIα结合可能是抗肥大药物干预的靶点,他汀治疗可能具有潜在作用。